Although heterozygous carriers of pathogenic CFTR variants do not develop cystic fibrosis, they may have an approximately 4–10-fold increased risk for pancreatitis and associated pancreatic injury due to elevated mucus levels, fibrosis, and cyst formation (Noone et al., 2001; Schneider et al., 2011; Steiner et al., 2011; Hegyi et al., 2016). This evidence concerns the gene CFTR and cystic fibrosis.